JPMorgan Chase & Co. Buys 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

JPMorgan Chase & Co. boosted its stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 4,826,425.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 772,244 shares of the company's stock after purchasing an additional 772,228 shares during the period. JPMorgan Chase & Co. owned approximately 2.77% of Vistagen Therapeutics worth $2,278,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. R Squared Ltd bought a new position in Vistagen Therapeutics in the 4th quarter worth $25,000. Jane Street Group LLC purchased a new stake in shares of Vistagen Therapeutics during the 3rd quarter valued at about $59,000. Virtu Financial LLC raised its position in shares of Vistagen Therapeutics by 30.5% during the 3rd quarter. Virtu Financial LLC now owns 20,210 shares of the company's stock valued at $61,000 after buying an additional 4,722 shares in the last quarter. HighTower Advisors LLC purchased a new stake in shares of Vistagen Therapeutics during the 3rd quarter valued at about $64,000. Finally, Prosperity Wealth Management Inc. purchased a new stake in shares of Vistagen Therapeutics during the 4th quarter valued at about $86,000. Institutional investors own 78.39% of the company's stock.

Vistagen Therapeutics Stock Performance

Vistagen Therapeutics stock remained flat at $2.29 during midday trading on Tuesday. 41,443 shares of the company were exchanged, compared to its average volume of 171,420. Vistagen Therapeutics, Inc. has a 12 month low of $1.90 and a 12 month high of $4.96. The company has a market capitalization of $66.09 million, a price-to-earnings ratio of -1.55 and a beta of 0.56. The stock has a 50-day simple moving average of $2.46 and a two-hundred day simple moving average of $2.71.

Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.02. The business had revenue of $230 billion during the quarter, compared to analyst estimates of $0.18 million. Vistagen Therapeutics had a negative return on equity of 48.12% and a negative net margin of 6,777.08%. On average, equities analysts forecast that Vistagen Therapeutics, Inc. will post -1.77 EPS for the current fiscal year.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.